Lancet

Mirum Announces Publication of Phase 3 MARCH Data in The Lancet Demonstrating Benefits of LIVMARLI (maralixibat) in patients with PFIC

Retrieved on: 
tisdag, maj 7, 2024
Biotechnology, Pharmaceutical, Health, Clinical Trials, IBAT, Liver disease, Hospital, Safety, The Lancet, TJP2, Cholestatic pruritus, Doctor of Philosophy, Research, Long-term care, Cholestasis, Bilirubin, Hepatology, Week, Data, Patient, Diarrhea, Itch, Serum, MDR3, Medication, Lancet, MYO5B, Growth, Pharmaceutical industry

Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced that data from the Phase 3 MARCH-PFIC study evaluating LIVMARLI® (maralixibat) oral solution in patients with PFIC was published in The Lancet Gastroenterology and Hepatology.

Key Points: 
  • Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced that data from the Phase 3 MARCH-PFIC study evaluating LIVMARLI® (maralixibat) oral solution in patients with PFIC was published in The Lancet Gastroenterology and Hepatology.
  • The MARCH-PFIC study was the largest, randomized, double-blind, placebo-controlled study in patients with PFIC, confirming the efficacy and safety of LIVMARLI, an IBAT inhibitor, across a broad genetic range of PFIC types.
  • “These data advance our understanding of LIVMARLI’s potential to provide meaningful improvements in pruritus and a number of parameters impacting patients with various PFIC types.
  • These data demonstrate the significant impact LIVMARLI can have in this severe cholestatic setting.”
    To read the full article, please visit the publication on The Lancet Gastroenterology and Hepatology’s website .

New Pandemic Agreement: Pharma Wins, Developing World Loses, says AHF Global Public Health Institute

Retrieved on: 
fredag, april 26, 2024
COVID-19, Public Policy, Other Policy Issues, Healthcare Reform, Pharmaceutical, Social Activism, Communications, General Health, Philanthropy, Advocacy Group Opinion, Infectious Diseases, Government, Foundation, AIDS, Health, United Nations, Public, University, IHR, PABS, Language, WHO, Community of practice, Learning, Pandemic, World Health Organization, INB, Policy, Infection, Intergovernmental, Conference, Research, Vaccine, Hoarding, Literature, International Health Regulations, AIDS Healthcare Foundation, Panel, Global health, Secretariat, AHF, United Nations General Assembly, Lancet, Letter, Pharmaceutical industry

As the final Intergovernmental Negotiating Body (INB) meeting of the World Health Organization (WHO) Pandemic Agreement approaches, the AIDS Healthcare Foundation and the AHF Global Public Health Institute are voicing significant concerns about the April 16, 2024, Proposal for the WHO Pandemic Agreement.

Key Points: 
  • As the final Intergovernmental Negotiating Body (INB) meeting of the World Health Organization (WHO) Pandemic Agreement approaches, the AIDS Healthcare Foundation and the AHF Global Public Health Institute are voicing significant concerns about the April 16, 2024, Proposal for the WHO Pandemic Agreement.
  • In addition to the GPMB and the IPPPR, the Panel for a Global Public Health Convention and Spark Street Advisors have also emphasized the critical need for independent monitoring.
  • Empty handshakes in Geneva will not prevent another global health disaster, nor will it keep countries from trampling over each other when the next pandemic comes.
  • To learn more about the AHF Global Public Health Institute, visit https://ahfinstitute.org/ .

Latin America CDC a Must, say Public Health Leaders and AHF

Retrieved on: 
fredag, april 26, 2024
COVID-19, Infectious Diseases, Hospitals, Hispanic, Other Health, Managed Care, Health, Consumer, General Health, Mark R. Dybul, Public, University, Pandemic, AIDS, Safety, Public health, World Health Organization, Policy, CDC, Dengue fever, AH1N1, Infection, LATAM, Research, Vaccine, Cayetano Heredia University, Emergency, AIDS Healthcare Foundation, Acquisition, Data collection, Private sector, Death, Faculty, AHF, Lancet

This new agency would seek to strengthen regional resilience against future health crises through collaboration and resource optimization among nations.

Key Points: 
  • This new agency would seek to strengthen regional resilience against future health crises through collaboration and resource optimization among nations.
  • Patricia J. Garcia, former health minister of Peru, principal professor of the Faculty of Public Health of the Universidad Peruana Cayetano Heredia, and one of the initiative's proponents, emphasized the importance of this regional collaboration: "The experience with COVID-19 demonstrated critical deficiencies in our public health infrastructure.
  • The LATAM CDC will serve as a fundamental pillar for prevention, preparedness, and rapid response to future health emergencies, thus strengthening our regional health sovereignty."
  • To learn more about the AHF Global Public Health Institute, visit https://ahfinstitute.org/ .

New Pandemic Agreement: Pharma Wins, Developing World Loses, says AHF Global Public Health Institute

Retrieved on: 
onsdag, april 24, 2024
COVID-19, Infectious Diseases, Public Policy, Government, AIDS, Health, Pharmaceutical, General Health, Other Policy Issues, United Nations, Public, University, IHR, PABS, Language, WHO, Community of practice, Learning, Pandemic, World Health Organization, INB, Policy, Infection, Intergovernmental, Conference, Research, Vaccine, Hoarding, Literature, International Health Regulations, AIDS Healthcare Foundation, Panel, Global health, Secretariat, AHF, United Nations General Assembly, Lancet, Letter, Pharmaceutical industry

As the final Intergovernmental Negotiating Body (INB) meeting of the World Health Organization (WHO) Pandemic Agreement approaches, the AIDS Healthcare Foundation and the AHF Global Public Health Institute are voicing significant concerns about the April 16, 2024 , Proposal for the WHO Pandemic Agreement.

Key Points: 
  • As the final Intergovernmental Negotiating Body (INB) meeting of the World Health Organization (WHO) Pandemic Agreement approaches, the AIDS Healthcare Foundation and the AHF Global Public Health Institute are voicing significant concerns about the April 16, 2024 , Proposal for the WHO Pandemic Agreement.
  • In addition to the GPMB and the IPPPR, the Panel for a Global Public Health Convention and Spark Street Advisors have also emphasized the critical need for independent monitoring.
  • Empty handshakes in Geneva will not prevent another global health disaster, nor will it keep countries from trampling over each other when the next pandemic comes.
  • To learn more about the AHF Global Public Health Institute, visit https://ahfinstitute.org/ .

New Pandemic Agreement: Pharma Wins, Developing World Loses, says AHF Global Public Health Institute

Retrieved on: 
onsdag, april 24, 2024
Public Policy, Government, Pharmaceutical, AIDS, General Health, Health, Other Policy Issues, Infectious Diseases, Advocacy Group Opinion, United Nations, Public, University, IHR, PABS, Language, WHO, Community of practice, Learning, Pandemic, World Health Organization, INB, Policy, Infection, Intergovernmental, Conference, Research, Vaccine, Hoarding, Literature, International Health Regulations, AIDS Healthcare Foundation, Panel, Global health, Secretariat, AHF, United Nations General Assembly, Lancet, COVID-19, Letter, Pharmaceutical industry

As the final Intergovernmental Negotiating Body (INB) meeting of the World Health Organization (WHO) Pandemic Agreement approaches, the AIDS Healthcare Foundation and the AHF Global Public Health Institute are voicing significant concerns about the April 16, 2024, Proposal for the WHO Pandemic Agreement .

Key Points: 
  • As the final Intergovernmental Negotiating Body (INB) meeting of the World Health Organization (WHO) Pandemic Agreement approaches, the AIDS Healthcare Foundation and the AHF Global Public Health Institute are voicing significant concerns about the April 16, 2024, Proposal for the WHO Pandemic Agreement .
  • In addition to the GPMB and the IPPPR, the Panel for a Global Public Health Convention and Spark Street Advisors have also emphasized the critical need for independent monitoring.
  • Empty handshakes in Geneva will not prevent another global health disaster, nor will it keep countries from trampling over each other when the next pandemic comes.
  • To learn more about the AHF Global Public Health Institute, visit https://ahfinstitute.org/ .

Nonprofit Visions2030 Moves to Counter Climate "Doom Loop" with Lumisphere Experience

Retrieved on: 
måndag, april 22, 2024
United Nations, System, Fear, Mentorship, Risk, Imagination, AI, Climate, The arts, Magic, Sphere, Eco-anxiety, Optimism, Consciousness, MOM, Multimedia, Paralysis, Lancet, Tourism

NEW YORK, April 22, 2024 /PRNewswire/ -- Visions2030, a New York City-based nonprofit, announced today a campaign to bring the Lumisphere Experience to communities, entertainment venues, and sites of cultural and international events across the United States and the globe. The campaign aims to conclude in 2030, the target year of the United Nations' Sustainable Development Goals, and is seeking relationships with strategic partners who want to be associated with an innovative initiative that inspires and activates more people to be involved in climate-related topics and issues.

Key Points: 
  • The globe is facing skyrocketing levels of climate anxiety and its paralysis, according to studies.
  • "With climate despair at an all-time high, the need for action is both urgent and overwhelming," says Visions2030 Founder Carey Lovelace.
  • A key metric of the Lumisphere campaign, she says, is to engage millions by 2030, shifting climate conversations, engaging communities, and activating participants.
  • To get involved with or learn more about the Lumisphere and the campaign, please visit www.visions2030.studio or email [email protected] .

Heatwaves Hit Harder for People with Disabilities: A Pusan National University Study Finds Increased Emergency Visits

Retrieved on: 
onsdag, april 17, 2024
Public, Climate change, Comorbidity, Heat, Risk, Hospital, Disability, Health, Vision, IPCC, Research, The Lancet, Sustainable Development Goals, Disability studies, Notifiable disease, Temperature, Ageing, Pusan National University, Lancet, Person, Nursing

Amid these concerns, the Intergovernmental Panel on Climate Change (IPCC) warns that heatwaves increase in intensity, frequency, and duration with every 0.5°C increase in temperature .

Key Points: 
  • Amid these concerns, the Intergovernmental Panel on Climate Change (IPCC) warns that heatwaves increase in intensity, frequency, and duration with every 0.5°C increase in temperature .
  • Despite these observations, however, there are limited studies on the impact of high temperatures on the health of people with disabilities.
  • Their study, published in the journal The Lancet Planetary Health, reveals disparities in admissions and medical expenses for individuals with disabilities and those without disabilities.
  • Title of original paper: Association between heat and hospitalizations in persons with disabilities: a nationwide case-crossover study

Convatec launches new Esteem Body™ with Leak Defense™

Retrieved on: 
måndag, april 15, 2024
Consensus, International, Skin, Tension, FEA, Research, Finite element method, McNichol, Convatec, Patent, NCD, Leak, Stoma, Lancet, Nursing

BRIDGEWATER, N.J., April 15, 2024 /PRNewswire/ -- Convatec, a leading global medical products and technologies company, today announces that it has launched Esteem Body™ with Leak Defense™ in the United States. 

Key Points: 
  • BRIDGEWATER, N.J., April 15, 2024 /PRNewswire/ -- Convatec, a leading global medical products and technologies company, today announces that it has launched Esteem Body ™ with Leak Defense™ in the United States.
  • The trend has driven abdominal topography changes and related challenges for ostomy care management, such as skin folds and complicated abdominal contours.
  • Convatec's Esteem Body™ offers eight different combinations of these key characteristics, with four 'tension locations' (split centrally and peripherally) across two different 'convex depths'.
  • (January 11, 2024) Impact of Stoma Baseplate Convexity on Tension and Compression Around the Stoma Site: A Finite Element Analysis.

Muscular Dystrophy Association’s Funding of Foundational Research Leads to New FDA Approved Treatment Duvyzat (givinostat) for Duchenne Muscular Dystrophy

Retrieved on: 
torsdag, mars 21, 2024
HDAC, Gene expression, Cell, Disease, MDA, Associate, Patient, Research, DNA, Public policy, University, Muscular dystrophy, Doctor of Philosophy, Muscular Dystrophy Association, Duchenne muscular dystrophy, Clinical trial, Therapy, Histone deacetylase inhibitor, Stair climbing, Plasma protein binding, FDA, Steroid, DMD, Parent, Lancet, Pediatrics, Human, Food, Pharmaceutical industry

"The approval of Duvyzat (givinostat) provides another significant treatment option for people living with Duchenne muscular dystrophy,” said Sharon Hesterlee, PhD, Chief Research Officer, MDA.

Key Points: 
  • "The approval of Duvyzat (givinostat) provides another significant treatment option for people living with Duchenne muscular dystrophy,” said Sharon Hesterlee, PhD, Chief Research Officer, MDA.
  • “Muscular Dystrophy Association’s funding was fundamental for the discovery of HDACi in the treatment of Duchenne muscular dystrophy.
  • “We’re excited to celebrate this additional treatment option for people living with Duchenne muscular dystrophy.
  • My son is an example,” said Jessica Curran, MDA family member and mother of Conner who lives with Duchenne muscular dystrophy.

Cybin Receives FDA Breakthrough Therapy Designation for its Novel Psychedelic Molecule CYB003 and Announces Positive Four-Month Durability Data in Major Depressive Disorder

Retrieved on: 
onsdag, mars 13, 2024
Alternative Medicine, Mental Health, Health, FDA, Clinical Trials, Pharmaceutical, Biotechnology, JAMA, Depression, Disability, Conference, BTD, Breakthrough therapy, Massachusetts General Hospital, Inc., Psychiatry, Clinical, Grammatical mood, Appetite, MDD, Data analysis, Patient, Knowledge, Disease, Causality, Sleep, Anhedonia, DNB, DSM-IV codes, MBBS, Suicidal ideation, Behavior, Cognition, Event, Hospital, Drug development, Safety, Injury, Multimedia, Plasma protein binding, Sadness, Lancet, BMJ, Pharmaceutical industry

If approved by the FDA, CYB003 would be the first known adjunctive psychedelic-based therapeutic for the treatment of MDD.

Key Points: 
  • If approved by the FDA, CYB003 would be the first known adjunctive psychedelic-based therapeutic for the treatment of MDD.
  • The designation of CYB003 as a breakthrough therapy acknowledges the significant unmet medical need for more effective treatments of MDD and supports CYB003’s potential for significant improvements over existing therapies.
  • With the robust durability data from our Phase 2 study in hand, we are ready to move forward expeditiously.
  • (2022) Response to acute monotherapy for major depressive disorder in randomized, placebo-controlled trials submitted to the US Food and Drug Administration: individual participant data analysis.